EFSA was requested by the European Commission to review and comment on the JECFA proposal to update its guideline on the evaluation of enzyme preparations used in the manufacture of foods. A comparison was made between the JECFA proposal and relevant EFSA guidance documents. Similarities were found in the approaches taken by JECFA and EFSA to the safety evaluation of food enzymes. However, the proposal for changes made by JECFA will result in significant differences. These differences are addressed in the technical report. In the view of EFSA, the proposals made by JECFA for changes to their guideline are likely to exacerbate the differences in approach taken by EFSA and JECFA.
Introduction
A decade after publishing its guidance on the evaluation of enzymes for use in foods (JECFA, 2006) , JECFA has announced the public consultation 1 on an update on the evaluation of enzyme preparations used in foods. All Interested parties are invited to submit written comments by 31 January 2020.
On 23 December 2019, the European Commission mandated EFSA to support the preparation of EU comments to the draft guideline of JECFA.
In line with EFSA's policy on openness and transparency, EFSA decided to answer this mandate in the format of a technical report and to publish it in EFSA Supporting Publications.
Terms of Reference
EFSA is invited to review the JECFA report and to identify aspects that would not be aligned with the EFSA approach for the safety evaluation of food enzymes. In such cases, a scientific rational calling JECFA to revise its document should be provided. The deadline is 27 January 2020.
Data and Methodologies
JECFA draft guideline is accessible at https://www.who.int/news-room/detail/28-11-2019-publicconsultation-on-the-evaluation-of-enzyme-preparations-used-in-foods.
The JECFA guideline was compared with the EFSA guidance documents (EFSA CEF Panel, 2009 and 2016; EFSA CEP Panel, 2019; EFSA BIOHAZ Panel, 2018) . The findings are analysed by EFSA in Section 3. The relevant page and line numbers in the JECFA draft guideline are reported as (JECFA, page: line).
3.
Analysis of the JECFA proposals in relation to the current EFSA practices 3.1. Substances under evaluation (JECFA, p28-29: 795-803, p49: Annex 4: 1249 -1250 JECFA's evaluation focuses on the "enzyme preparation" whilst EFSA evaluates, whenever possible, the "food enzyme".
"Enzyme preparation", as defined by JECFA, represents the article of commerce used in food production, which consists of the active substance (e.g. enzyme concentrate) and formulation ingredients.
"Food enzyme", as defined in the European legislation (Regulation (EC) No 1332/2008) 2 , is the intermediate product before the formulation step. As the manufacturing process consists of multiple steps, "food enzyme" can correspond to a range of products obtained spanning from early stage (e.g. a crude filtrate) to later stage (such as an enzyme concentrate).
The difference between an "enzyme preparation" and a "food enzyme" lies mainly in the formulation ingredients. Formulation ingredients (excipients) are authorized food additives or food ingredients functioning as stabilizers, preservatives, carriers and diluents. They can constitute a significant portion (70-90%, w/w) of an "enzyme preparation", particularly when marketed in solid form. Under the European legislation, the safety of these excipients is evaluated and authorized separately from the safety of a food enzyme in the EU. In principle, substances used as excipients are chemically stable and not reactive. Therefore, it is scientifically sound to focus the evaluation on the enzyme protein(s) and other organic impurities that might arise from production of the food enzyme (collectively referred to as Total Organic Solides -TOS). This is particularly important when deciding upon the suitability of the test material used in toxicological tests.
1 Accessible at https://www.who.int/news-room/detail/28-11-2019-public-consultation-on-the-evaluation-ofenzyme-preparations-used-in-foods 2 Regulation ( For the assessment of physiochemical and microbiological parameters, EFSA proposes to use data generated from both the "food enzyme" and the "enzyme preparation". For toxicological tests, EFSA agrees with JECFA to use the "enzyme concentrate", which considers by EFSA as essentially equivalent to the EU definition of "food enzyme".
Microbial source of the enzyme
Presumption of safety (JECFA, p12-13: 291-319, p26-27: 709-760, p33: 983-996, p41: 1220 (JECFA, p12-13: 291-319, p26-27: 709-760, p33: 983-996, p41: -1232 JECFA proposes to recognise a microorganism as a safe source for human consumption, (and therefore dispense with the need for further toxicological examination), based on empirical findings (no toxicity of fermented products) at the species level. EFSA always considers the safety of a microorganism at the strain level. However, EFSA does maintain a list of microorganisms (the QPS list) for which there is substantial documented evidence that a taxonomic unit (a species for bacteria and yeast) is presumed to be safe. If scientific knowledge identifies a specific, or more generally applicable, hazard related to a species, e.g., acquired antimicrobial resistance, which can be tested at the strain or product level, a "qualification" to exclude that hazard maybe established. Microorganisms included in the QPS list are still subject to a safety assessment, although with fewer requirements. The data require in each application must confirm the unambiguous identification of the organism and that any applicable qualifications are met (e.g., absence of acquired antimicrobial resistance). Some microbial groups, such as filamentous fungi, are excluded from the QPS list. For fungi, this exclusion is based on the possible production of fungal secondary metabolites for which information on their toxic effects on humans and animals is insufficient to guarantee safety (EFSA BIOHAZ Panel, 2018) .
EFSA has used QPS as a system of presumption of safety, which is similar to that described by JECFA (Class I -type iii) for over a decade. EFSA has concerns over the alignment of criteria used to populate the list proposed by JECFA and the mechanism available for its maintenance. EFSA currently reviews its QPS list on a regular basis.
The safe strain lineage approach as described and considered by JECFA applicable to some species of Bacillus and Aspergillus is generally insufficient to guarantee the absence of hazard. For example, any mutation or modification of the genome may lead to the activation or induction of the expression of toxic components (e.g., secondary metabolites by filamentous fungi). Moreover, the fact that certain organisms can be used safely under certain conditions does not mean that they will behave equally in all possible conditions.
Genetically modified microorganisms (JECFA, p11: 260-270, p34: 1008 (JECFA, p11: 260-270, p34: -1015 : Table 4 , p43-44:Annex 3: entry 13)
EFSA has revised and updated its criteria for the characterisation of production strains including genetically modified microorganisms, by focusing on whole genome sequence analysis as pivotal for the safety assessment (EFSA CEP Panel, 2019). Data on whole genome sequence eliminate the need for detailed information concerning the genetic modification steps as retained in the JECFA guideline.
EFSA has also extended the QPS concept to include GM microorganisms, provided that the genetic modification does not raise safety concerns (EFSA BIOHAZ Panel, 2018).
Absence of viable cells and DNA
(JECFA, p32-33: Table 2) For microorganisms other than those qualified for QPS, EFSA requires experimental evidence of the absence of the production strain in the food enzyme. This rules out concerns about possible pathogenicity, particularly when little is known about the biology of the microbial group. This requirement is not contemplated by JECFA.
EFSA also requires evidence of the absence of DNA from the production strain in the food enzyme for all GMMs and for those non-GMMs containing the acquired antimicrobial resistance genes. (JECFA, JECFA proposes to categorise the enzymes into three types for which toxicological testing is not required. This would not be fully compatible with the European legislation or EFSA practice.
JECFA proposal for the classification of enzymes
JECFA Class I: Enzymes derived from sources which are considered safe for consumption and for which toxicological evaluations are NOT normally required.
Type i: Enzymes obtained from edible tissues of plants or animals commonly used as foods I(i).
In principle, EFSA agrees with JECFA, provided that those enzymes demonstrate no adverse effects on human health when consumed to a comparable extent to the tissues from which they are derived. Information on allergenicity would be sought, but specific studies may not have to be requested.
Type ii: Enzymes derived from micro-organisms that are traditionally accepted as constituents of foods or are normally used in the preparation of foods I(ii).
Many microorganisms traditionally used in food are known to be able to produce toxins (e.g. Penicillium roqueforti, Aspergillus oryzae). In addition, "traditional" is a subjective concept which varies with cultural and regional habits. EFSA does not agree with the arguments made for waiving of the need for toxicological studies for this group of enzymes. EFSA agrees with JECFA that a full dataset is required for the safety assessment. (JECFA, p45 :Annex 3: entry 20)
Impurity
EFSA currently requires representative batch data for a minimum of three batches compared with JECFA which proposes a minimum of five non-consecutive batches. EFSA acknowledges the value of this requirement, provided that it is recognized that, for some low volume enzymes or enzyme products in development, five non-consecutive batches would not be feasible.
JECFA proposes analytical confirmation that an enzyme does not contain toxic secondary metabolites known to be synthesized by the production organism or related species as an alternative to genotoxicity tests. EFSA welcomes experimental data confirming the absence of specific toxins, the use of in silico methods and information from WGS of the absence or deletion/disruption of genes encoding protein essential to the biosynthesis of compounds of potential concern. As pathway analysis and the annotation of genomes improves, it may well become possible and preferable to use such data in place of toxicity studies. However, at present EFSA does not consider this alternative viable for the following reasons:
 Such confirmation would be limited to our knowledge on the capacity of the production strain or related species to produce toxic compounds. While traditionally, the enzyme industry has utilized a relatively narrow range of production organisms for which a body of knowledge has accumulated over time, the search for novel catalytic functions or properties has led to the isolation and use of organisms whose biology remains largely unknown.
 Such confirmation would be possible only for known substances for which validated analytical methodologies/standards and toxicological data are already available.
Therefore, EFSA at present considers it necessary to retain the reassurance offered by the battery of toxicological tests confirming the absence of toxic effects arising from metabolites of the production organism. (JECFA, p47 : Annex 3: entry 28) Whenever toxicological tests are deemed necessary, as the starting point both JECFA and EFSA require a battery of two in vitro genotoxicity assays to evaluate the presence of mutations and of chromosomal aberrations as well as one in vivo repeated dose 90-day oral toxicity test in rodents to evaluate systemic toxicity. The in vitro micronucleus test in mammalian cells is recommended instead of chromosomal aberration test to cover the three genetic endpoints of genotoxicity (gene mutation, structural and numerical chromosomal aberration).
Toxicology
For new applications on food enzymes, EFSA recommends performing tests according to the latest versions of OECD guidelines, i.e. for repeated dose 90-day oral toxicity study according to OECD 408 (2018) in which also endocrine-sensitive endpoints were added. (JECFA, p7-9: 128-186, p29-30: 806-877, p33-34: 1000 -1005 JECFA recognises the limitation of simulated gastric fluid studies in excluding the possible allergenicity of a protein, nevertheless, still recommends in vitro digestibility tests. EFSA does not request such tests in the context of an allergenicity assessment, because of the lack of evidence of their predictability. EFSA considers such tests of marginal value for the assessment of allergenicity.
Allergenicity

3.7.
Dietary exposure (JECFA, p47: Annex3: entry 30) JECFA accepts different data sources to estimate dietary exposure under the assumption that the enzyme TOS always remains in the final foods at 100%. In contrast, EFSA considers also the potential removal of enzyme TOS during processing, to guide the dietary exposure assessment. If sufficient evidence is available to indicate absence or negligible (e.g. <1%) transfer of TOS into the final food, and if the food process can be reasonably assumed to be the same wherever the enzyme is used (e.g. starch processing for the production of glucose syrup and other starch hydrolysates), no dietary exposure estimate is calculated (Annex B in EFSA CEF Panel, 2016).
In the absence of such information, exposure is estimated based on actual food consumption data collected through national dietary surveys, and which is stored in the EFSA Comprehensive Food Consumption Database. The use of the budget method which is still accepted by JECFA has been replaced by EFSA with actual food consumption data-based assessment methodology (EFSA CEF Panel, 2016) . Only in those circumstances, where such data are not available for a specific population or for niche food products, alternative sources are considered. EFSA would encourage, wherever possible, the use of actual consumption data.
3.8.
Factors possibly leading to quicker evaluation (JECFA, p32:942-1039 (JECFA, p32:942- , p33:971-980, p34:1024 (JECFA, p32:942- -1028 Based on the fundamental chemical differences between flavouring substances (e.g., low molecular weight and non-polar and volatile substances) and enzymes (high molecular weight, polar and non-volatile substances), a read-cross or parallel assessment of these two classes of components should not be made.
The presumption of safety of food enzymes from different sources on the basis of similar catalytic activities (read-across) is not acceptable. The focus of any assessment of a food enzyme is the associated TOS and, with the exception of allergenicity, only rarely the declared activity itself. The composition and any potential hazards presented by TOS is determined by the metabolism of the individual source, the materials used in its cultivation/extraction and the downstream processing applied. For the vast majority of food enzymes, potential hazards are thus independent of the declared catalytic activity and an extrapolation based solely on catalytic activity is considered by EFSA as unsafe.
Grouping enzymes by catalytic activity is not possible, as enzymes having the same catalytic activity may have different primary, secondary and tertiary structures. Different structures will result in a different potential to cause allergenic reactions or intolerance.
Conclusion
There are similarities in the approaches taken by JECFA and EFSA to the safety evaluation of food enzymes. However, the proposals made by JECFA will result in significant differences. These differences are addressed in the text above. In the view of EFSA, the proposals made by JECFA for changes to its guideline are likely to exacerbate the differences in approach taken by EFSA and JECFA.
